Pharmanovia Enters Into an Exclusive Licensing Agreement With Aeterna Zentaris for the First and Only Orally Administered Approved Medicine for the Diagnosis of Growth Hormone Deficiency in Adults
Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its endocrinology portfolio with a new licensing agreement for GHRYVELIN™ (macimorelin), a novel medicine used for diagnosing Adult Growth Hormone Deficiency (AGHD) from Aeterna Zentaris.
The agreement gives Pharmanovia the exclusive commercial rights in the UK and EEA.
AGHD is a rare and serious condition that affects 2 to 3 people in 10,000 with significant risk of morbidity and reduced quality of life. It is underdiagnosed and often missed in patients.1
It is characterised by a number of variable and common symptoms including reduced energy levels, altered body composition, osteoporosis (reduced bone mineral density), reduced muscle strength, lipid abnormalities such as increased LDL cholesterol, insulin resistance, and impaired cardiac function.2
Pharmanovia CEO, Dr James Burt commented; ‘’Endocrinology is the largest of our four core therapy areas and the in-licensing of this important novel medicine, the second in-licensing deal of a novel medicine in almost as many weeks, speaks to our ability to in-licence novel, complementary products in the therapeutic settings we support.”
“We are well placed to use the knowledge and the platform we’ve built through our current endocrinology work to ensure that more patients get the diagnosis they need for this rare and serious condition. Furthermore today’s announcement presents a rare opportunity to license in a medicine that naturally synergises with one of the core growth products in our current portfolio.”
Dr Klaus Paulini, CEO of Aeterna Zentaris, added: “Pharmanovia has expertise marketing diagnostic testing solutions combined with an established footprint in endocrinology across Europe, so this partnership was a natural choice. We’re excited to leverage their knowledge to ensure that more patients benefit from an improved testing experience and reduction in unnecessary treatment for patients.”
About Pharmanovia
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by enhancing established medicines either by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and through strategic partnerships.
Our diverse and growing team operate in over 160 countries across the globe, delivering high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.
About Aeterna Zentaris
Aeterna Zentaris is a specialty biopharmaceutical company developing and commercialising a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen™; Ghryvelin®), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need, in collaboration with Novo Nordisk.
About Macimorelin
Macimorelin is marketed under the brand name GHRYVELIN™ (macimorelin) in the UK and European Economic Area.
GHRYVELIN™ a ghrelin agonist, is an orally active small molecule that stimulates the secretion of growth hormone from the pituitary gland. Stimulated growth hormone levels are measured in blood samples after oral administration of GHRYVELIN™ for the assessment of AGHD. of GHRYVELIN™ was granted in 2019, based on Phase III data showing that oral macimorelin provides accuracy comparable to that of standard insulin tolerance testing (ITT)4, but has a more favourable safety profile compared to ITT. Oral GHRYVELIN™ also reduces false positive test results, helping to avoid unnecessary treatment of patients.3
References
1 J Endocr Soc. 2022 Jul 1; 6(7): bvac077. Andrew R Hoffman, Tracy Mathison, Deno Andrews, Kristine Murray, Nicky Kelepouris, and Maria Fleseriu - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165431/ -last accessed 1.3.2023
2 Yuen KCJ, Biller BMK, Radovick S, et al -. Endocr Pract. 2019;25(11):1191-1232. https://pubmed.ncbi.nlm.nih.gov/31760824/ - last accessed 1.3.2023
3 Garcia JM et al. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab, 2018, 103(8): 3083-3093 - https://pubmed.ncbi.nlm.nih.gov/29860473/ - last accessed 1.3.2023
4 https://www.ema.europa.eu/en/documents/assessment-report/ghryvelin-previously-macimorelin-aeterna-zentaris-epar-public-assessment-report_en.pdf – last accessed 1.3.2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005846/en/
Contact information
For further information:
Alison Dyson, Director of Communications, Pharmanovia
07442 256310/ alison.dyson@pharmanovia.com
Or pharmanovia@67health.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Armis Secures Italy’s Primary Public Healthcare Provider for the City of Naples as Cyber Threats Increase13.1.2026 15:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced that ASL Napoli 1 Centro, Italy’s primary public healthcare provider for the City of Naples, is securing its attack surface using Armis Centrix™, the Armis Cyber Exposure Management Platform. Prior to working with Armis, ASL Napoli 1 Centro did not have the tools or capabilities to monitor physical and virtual assets in real time, which posed a challenge for its security and compliance. Armis Centrix™ was deployed with a clear goal: to provide ASL Napoli 1 Centro with a comprehensive, real-time view of its connected biomedical inventory and the associated risks to the overall environment. “Time-to-value was practically immediate; Armis began delivering valuable information as soon as the system was activated and connected to our internal network,” said Fulvio Paone, Director of the ICT and Digital Transformation Unit at ASL Napoli 1 Centro. “Armis has given us visibility into a critical area. This isn’t just about
Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge13.1.2026 15:00:00 EET | Press release
Opengear, a Digi International company (NASDAQ, DGII), today announced two new additions to its Network Resilience Platform: the CM8000 Series and the OM1300 Series. These next generation devices deliver compact, flexible, and automation-ready out-of-band infrastructure designed for a time when outages are increasing and distributed sites continue to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113807672/en/ Opengear Introduces CM8000 and OM1300: Two New Paths to Network Resilience as Outages Surge According to Opengear research, 84 percent of CIOs and CISOs have experienced a rise in outages over the past two years. The CM8000 Series and OM1300 Series were purpose-built to ensure that IT teams maintain access and control even when the production network is unavailable. The two series provide complementary approaches: CM8000 Series A serial-first recovery platform with integrated power control for core branches,
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 15:00:00 EET | Press release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
ExaGrid’s FY 2025 Results—A Record Quarter and a Record Year for Company13.1.2026 15:00:00 EET | Press release
ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that it had record bookings and record revenue in the fourth quarter ending December 31, 2025, and had a record-year for bookings and revenue for 2025. ExaGrid broke many records in the quarter (Q4 2025), including: Record overall revenue and bookings Record revenue and bookings for new customers Record revenue and bookings for existing customer repeat orders Record 202 new logo customers in the quarter Record 88 six-figure new logo customers 3 seven-figure new logo customer deals In addition, ExaGrid had a record bookings and revenue year in 2025 and remained P&L, EBITDA, and free cash flow positive for the 20th consecutive quarter. The company is 100% debt-free, demonstrating strong financial health as a company. ExaGrid added 202 n
Wolfspeed Achieves 300mm Silicon Carbide (SiC) Technology Breakthrough13.1.2026 15:00:00 EET | Press release
Wolfspeed, Inc. (NYSE: WOLF), a global leader in silicon carbide technology, today announced a significant industry milestone with the successful production of a single crystal 300mm (12-inch) silicon carbide wafer. Backed by one of the industry’s largest and foundational silicon carbide IP portfolios, comprising more than 2,300 issued and pending patents worldwide, Wolfspeed is pioneering the transition to 300mm technology, establishing a clear path to future volume commercialization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113487095/en/ Wolfspeed produces 300mm silicon carbide wafer. This technology advancement represents a major step forward for next-generation computing platforms, immersive AR/VR systems, and high-efficiency, advanced power devices. By expanding silicon carbide to 300mm, Wolfspeed is unlocking new performance thresholds and manufacturing scalability for some of the world’s most demanding semico
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom